51 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Limited
5 Sep 24
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
4:20pm
of Section 21E of the Private Securities Litigation Reform Act of 1995.
INVESTOR CONTACT:
David Szekeres
President
dszekeres@connectpharm.com
6-K
CNTB
Connect Biopharma Holdings Limited
5 Sep 24
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
4:20pm
statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Overview
We
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Limited
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
INVESTOR CONTACT:
Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com
6-K
CNTB
Connect Biopharma Holdings Limited
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Exhibit Index
Exhibit
6-K
EX-99.1
cf2t1wr1mvzf 3p
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
6-K
rr8zp79qy5qvws2tt
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
EX-99.1
s61uu0oro0nts6
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
EX-99.2
3wumq4 2npigczk9
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
6-K
vnokj
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
px2v b1dt
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
qmv2 nlt8f8vv
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
64gzb5
1 Jun 23
Current report (foreign)
4:24pm
6-K
kufp7fvxec
1 Jun 23
Current report (foreign)
4:24pm
6-K
EX-99.1
2xnhrh0
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
4m941fvj
30 Dec 22
Connect Biopharma Provides Business and Clinical Development Program Update
8:00am
6-K
EX-99.1
dsx 5emux5wa5a0beh3n
30 Dec 22
Connect Biopharma Provides Business and Clinical Development Program Update
8:00am
6-K
oud4f1opt5498wggsy
4 Oct 22
Current report (foreign)
7:16am
6-K
lmqd0f
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm